vs
帕可Bio（PACB）与RE/MAX Holdings, Inc.（RMAX）财务数据对比。点击上方公司名可切换其他公司
RE/MAX Holdings, Inc.的季度营收约是帕可Bio的1.6倍（$71.1M vs $44.6M），RE/MAX Holdings, Inc.净利率更高（2.0% vs -90.4%，领先92.5%），帕可Bio同比增速更快（13.8% vs -1.8%），RE/MAX Holdings, Inc.自由现金流更多（$33.5M vs $-19.9M），过去两年帕可Bio的营收复合增速更高（7.3% vs -4.7%）
太平洋生物科学（加利福尼亚）公司是2004年成立的美国生物技术企业，专注于研发生产基因测序相关设备，还可实现新型实时生物观测。公司拥有两大核心测序平台：基于零模波导特性的单分子实时测序平台（SMRT），以及采用天然核苷酸、无损伤掺入完成DNA结合与延伸的结合测序技术（SBB）平台。
RE/MAX是全球知名的房地产特许经营机构，业务遍布全球一百多个国家和地区，旗下拥有数千家门店，总计超过十万名房产经纪人，在国际房产中介领域拥有极高的品牌知名度与市场影响力。
PACB vs RMAX — 直观对比
营收规模更大
RMAX
是对方的1.6倍
$44.6M
营收增速更快
PACB
高出15.7%
-1.8%
净利率更高
RMAX
高出92.5%
-90.4%
自由现金流更多
RMAX
多$53.4M
$-19.9M
两年增速更快
PACB
近两年复合增速
-4.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $44.6M | $71.1M |
| 净利润 | $-40.4M | $1.4M |
| 毛利率 | 37.1% | — |
| 营业利润率 | -92.3% | 13.1% |
| 净利率 | -90.4% | 2.0% |
| 营收同比 | 13.8% | -1.8% |
| 净利润同比 | -1802.7% | -75.2% |
| 每股收益（稀释后） | $-0.11 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PACBRMAX
| Q4 25 | $44.6M | $71.1M | ||
| Q3 25 | $38.4M | $73.2M | ||
| Q2 25 | $39.8M | $72.8M | ||
| Q1 25 | $37.2M | $74.5M | ||
| Q4 24 | $39.2M | $72.5M | ||
| Q3 24 | $40.0M | $78.5M | ||
| Q2 24 | $36.0M | $78.5M | ||
| Q1 24 | $38.8M | $78.3M |
净利润PACBRMAX
| Q4 25 | $-40.4M | $1.4M | ||
| Q3 25 | $-38.0M | $4.0M | ||
| Q2 25 | $-41.9M | $4.7M | ||
| Q1 25 | $-426.1M | $-2.0M | ||
| Q4 24 | $2.4M | $5.8M | ||
| Q3 24 | $-60.7M | $966.0K | ||
| Q2 24 | $-173.3M | $3.7M | ||
| Q1 24 | $-78.2M | $-3.4M |
毛利率PACBRMAX
| Q4 25 | 37.1% | — | ||
| Q3 25 | 41.4% | — | ||
| Q2 25 | 36.9% | — | ||
| Q1 25 | -3.7% | — | ||
| Q4 24 | 25.6% | — | ||
| Q3 24 | 25.0% | — | ||
| Q2 24 | 16.5% | — | ||
| Q1 24 | 29.1% | — |
营业利润率PACBRMAX
| Q4 25 | -92.3% | 13.1% | ||
| Q3 25 | -101.1% | 25.0% | ||
| Q2 25 | -112.8% | 19.3% | ||
| Q1 25 | -1154.5% | 7.2% | ||
| Q4 24 | -390.1% | 5.9% | ||
| Q3 24 | -160.3% | 19.4% | ||
| Q2 24 | -488.3% | 20.6% | ||
| Q1 24 | -209.6% | 5.8% |
净利率PACBRMAX
| Q4 25 | -90.4% | 2.0% | ||
| Q3 25 | -98.9% | 5.4% | ||
| Q2 25 | -105.4% | 6.4% | ||
| Q1 25 | -1146.8% | -2.6% | ||
| Q4 24 | 6.0% | 8.0% | ||
| Q3 24 | -151.9% | 1.2% | ||
| Q2 24 | -481.3% | 4.7% | ||
| Q1 24 | -201.4% | -4.3% |
每股收益（稀释后）PACBRMAX
| Q4 25 | $-0.11 | — | ||
| Q3 25 | $-0.13 | — | ||
| Q2 25 | $-0.14 | — | ||
| Q1 25 | $-1.44 | — | ||
| Q4 24 | $-0.44 | — | ||
| Q3 24 | $-0.22 | — | ||
| Q2 24 | $-0.64 | — | ||
| Q1 24 | $-0.29 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $279.5M | $118.7M |
| 总债务越低越好 | — | $432.2M |
| 股东权益账面价值 | $5.3M | $452.4M |
| 总资产 | $784.1M | $582.5M |
| 负债/权益比越低杠杆越低 | — | 0.96× |
8季度趋势，按日历期对齐
现金及短期投资PACBRMAX
| Q4 25 | $279.5M | $118.7M | ||
| Q3 25 | $298.7M | $107.5M | ||
| Q2 25 | $314.7M | $94.3M | ||
| Q1 25 | $343.1M | $89.1M | ||
| Q4 24 | $389.9M | $96.6M | ||
| Q3 24 | $471.1M | $83.8M | ||
| Q2 24 | $509.8M | $66.1M | ||
| Q1 24 | $561.9M | $82.1M |
总债务PACBRMAX
| Q4 25 | — | $432.2M | ||
| Q3 25 | — | $433.3M | ||
| Q2 25 | — | $434.4M | ||
| Q1 25 | — | $435.3M | ||
| Q4 24 | — | $436.2M | ||
| Q3 24 | — | $437.2M | ||
| Q2 24 | — | $438.1M | ||
| Q1 24 | — | $439.0M |
股东权益PACBRMAX
| Q4 25 | $5.3M | $452.4M | ||
| Q3 25 | $36.1M | $448.1M | ||
| Q2 25 | $61.5M | $442.4M | ||
| Q1 25 | $91.6M | $433.5M | ||
| Q4 24 | $506.6M | $429.5M | ||
| Q3 24 | $453.1M | $423.1M | ||
| Q2 24 | $492.7M | $418.4M | ||
| Q1 24 | $649.0M | $412.0M |
总资产PACBRMAX
| Q4 25 | $784.1M | $582.5M | ||
| Q3 25 | $803.2M | $582.2M | ||
| Q2 25 | $825.5M | $574.8M | ||
| Q1 25 | $860.8M | $571.4M | ||
| Q4 24 | $1.3B | $581.6M | ||
| Q3 24 | $1.5B | $578.6M | ||
| Q2 24 | $1.5B | $571.4M | ||
| Q1 24 | $1.7B | $566.7M |
负债/权益比PACBRMAX
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | 1.02× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.05× | ||
| Q1 24 | — | 1.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-19.1M | $40.9M |
| 自由现金流经营现金流 - 资本支出 | $-19.9M | $33.5M |
| 自由现金流率自由现金流/营收 | -44.6% | 47.1% |
| 资本支出强度资本支出/营收 | 1.9% | 10.4% |
| 现金转化率经营现金流/净利润 | — | 28.39× |
| 过去12个月自由现金流最近4个季度 | $-114.1M | $56.8M |
8季度趋势，按日历期对齐
经营现金流PACBRMAX
| Q4 25 | $-19.1M | $40.9M | ||
| Q3 25 | $-18.7M | $17.7M | ||
| Q2 25 | $-29.4M | $4.6M | ||
| Q1 25 | $-44.1M | $5.7M | ||
| Q4 24 | $-30.6M | $59.7M | ||
| Q3 24 | $-45.5M | $17.6M | ||
| Q2 24 | $-54.3M | $15.9M | ||
| Q1 24 | $-75.7M | $9.4M |
自由现金流PACBRMAX
| Q4 25 | $-19.9M | $33.5M | ||
| Q3 25 | $-18.8M | $16.4M | ||
| Q2 25 | $-29.9M | $2.9M | ||
| Q1 25 | $-45.4M | $4.0M | ||
| Q4 24 | $-32.3M | $53.0M | ||
| Q3 24 | $-46.3M | $16.3M | ||
| Q2 24 | $-55.7M | $14.0M | ||
| Q1 24 | $-79.6M | $6.8M |
自由现金流率PACBRMAX
| Q4 25 | -44.6% | 47.1% | ||
| Q3 25 | -48.9% | 22.4% | ||
| Q2 25 | -75.3% | 4.0% | ||
| Q1 25 | -122.3% | 5.3% | ||
| Q4 24 | -82.3% | 73.2% | ||
| Q3 24 | -115.7% | 20.8% | ||
| Q2 24 | -154.8% | 17.8% | ||
| Q1 24 | -205.0% | 8.6% |
资本支出强度PACBRMAX
| Q4 25 | 1.9% | 10.4% | ||
| Q3 25 | 0.2% | 1.8% | ||
| Q2 25 | 1.4% | 2.2% | ||
| Q1 25 | 3.7% | 2.3% | ||
| Q4 24 | 4.1% | 9.1% | ||
| Q3 24 | 2.0% | 1.7% | ||
| Q2 24 | 4.1% | 2.4% | ||
| Q1 24 | 10.0% | 3.3% |
现金转化率PACBRMAX
| Q4 25 | — | 28.39× | ||
| Q3 25 | — | 4.45× | ||
| Q2 25 | — | 0.97× | ||
| Q1 25 | — | — | ||
| Q4 24 | -12.93× | 10.28× | ||
| Q3 24 | — | 18.22× | ||
| Q2 24 | — | 4.29× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PACB
| Products | $39.0M | 87% |
| Service And Other | $5.7M | 13% |
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
